You are here

liver disease

Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay

Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay

Fierce Biotech

Intercept Pharma

CymaBay Therapeutics

Flag link:

3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer

3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer

Motley Fool

cardiovascular disease

Flag link:

Genethon’s Gene Therapy for Rare Liver Disease Shows Promising Early-Stage Results

Genethon’s Gene Therapy for Rare Liver Disease Shows Promising Early-Stage Results

BioSpace

Crigler-Najjar Syndrome

clinical trials

Flag link:

Ipsen and Genfit to file for EMA and FDA approval for elafibranor

Ipsen and Genfit to file for EMA and FDA approval for elafibranor

Clinical Trials Arena

primary biliary cholangitis

Flag link:

After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use

After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use

Fierce Pharma

Flag link:

Mallinckrodt secures FDA approval — but not without warning

Mallinckrodt secures FDA approval — but not without warning

Endpoints

hepatorenal syndrome

Flag link:

Vertex, Verve team up to develop a gene editing drug for liver disease

Vertex, Verve team up to develop a gene editing drug for liver disease

Biopharma Dive

Verve Therapeutics

Flag link:

Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference

Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference

BioSpace

Arrowhead Pharmaceuticals

Flag link:

Laekna Therapeutics Raises $61 Million in Series D financing

Laekna Therapeutics Raises $61 Million in Series D financing

BioSpace

Laekna Therapeutics

Flag link:

Intercept sells international rights to liver drug in $400M deal

Intercept sells international rights to liver drug in $400M deal

BioPharma Dive

Intercept Pharma

Flag link:

89bio gains a little more confidence in NASH treatment with new hormone data

89bio gains a little more confidence in NASH treatment with new hormone data

Fierce Biotech

Flag link:

Digital health firm ChronWell raises $6m for liver disease toolkit

Digital health firm ChronWell raises $6m for liver disease toolkit

Pharmaforum

digital therapeutics

patient managment

Flag link:

CRISPR-editing biotech Arbor Bio adds $215M for liver, CNS disease therapies

CRISPR-editing biotech Arbor Bio adds $215M for liver, CNS disease therapies

MedCity News

Arbor Biotechnologies

Flag link:

Genevant, Takeda Enter Collab to Find a Cure for Rare Liver Diseases

Genevant, Takeda Enter Collab to Find a Cure for Rare Liver Diseases

BioSpace

Genevant Sciences

drug development

Flag link:

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

Pharmaforum

Flag link:

Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B

Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B

Fierce Biotech

Spark Therapeutics

Flag link:

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

Xconomy

Arrowhead Pharmaceuticals

clinical trials

Flag link:

Mirum Pharmaceuticals Files for $63 Million Offering

Mirum Pharmaceuticals Files for $63 Million Offering

CP WIre

Mirum Pharmaceuticals

Flag link:

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Endpoints

Flag link:

3 Things to Watch From the Pharmaceutical Industry's Liver Meeting

3 Things to Watch From the Pharmaceutical Industry's Liver Meeting

Motley Fool

The Liver Meeting

Assembly Biosciences

CymaBay Therapeutics

Madrigal Pharmaceuticals

Flag link:

Pages